Authors’ Reply

Journal of the American Society of Nephrology, vol. 32, pp. 1005–1007

Abstract

In a letter to the editor regarding the recently published article titled “Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan,”[1][1] Liu et al. [2][2] note that our manuscript does not provide

Authors 4

1. Tadao Akizawa

   SHOWA Medical University

   Affiliation as printed

   Department of Nephrology, Showa University School of Medicine, Tokyo, Japan

2. Manabu Iwasaki

   Yokohama City University

   Affiliation as printed

   Department of Data Science, Yokohama City University, Yokohama, Japan

3. Yusuke Yamaguchi

   Astellas Pharma (Japan)

   Affiliation as printed

   Japan-Asia Data Science, Development, Astellas Pharma, Inc., Tokyo, Japan

4. Yoshikatsu Majikawa

   Astellas Pharma (Japan)

   Affiliation as printed

   Japan-Asia Clinical Development 2, Development, Astellas Pharma, Inc., Tokyo, Japan